|
|
 Previous Article | Table of Contents | Next Article 
Phenotypic and functional characterization of T-BAM (CD40 ligand)+ T- cell
non-Hodgkin's lymphoma
G Inghirami, S Lederman, MJ Yellin, A Chadburn, L Chess and DM Knowles
Department of Pathology, College of Physicians and Surgeons of Columbia
University, New York, NY.
The precise mechanisms regulating T-helper function have been intensively
investigated. We and others have recently identified a new
T-cell-B-cell-activating molecule called T-BAM that directs B-cell
differentiation by interacting with the CD40 molecule on B cells. Using a
specific monoclonal antibody against T-BAM (5C8), we have previously shown
that T-BAM expressing T cells are predominantly CD4+CD8- and in normal
lymphoid tissue have a unique distribution. However, no information has
been obtained regarding the phenotype and functional properties of human
neoplastic T cells. Therefore, we investigated T- BAM expression
immunohistochemically in 87 well-characterized T-cell non-Hodgkin's
lymphomas and lymphoid leukemias (LL). We found that 21/81 neoplasms
expressed detectable T-BAM and these positive tumors belong almost
exclusively to the CD4+CD8- subtype. In addition, to determine whether
T-BAM expression could be induced on T-BAM-LL cells, we activated T-BAM-LLs
in vitro and showed that T-BAM could be upregulated only in CD4+CD8-
tumors. Our studies clearly show that T- BAM is constitutively expressed in
a large number of T-cell neoplasms with a relative mature phenotype
(CD4+CD8-) and that only CD4+ neoplastic T cells can be induced in vitro to
express this molecule. Additional studies are necessary to identify the
biologic significance of T-BAM expression and its potential and clinical
implications.
Volume 84,
Issue 3,
pp. 866-872,
08/01/1994
Copyright © 1994 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Aldinucci, D. Poletto, D. Lorenzon, P. Nanni, M. Degan, K. Olivo, B. Rapana, A. Pinto, and V. Gattei
CD26 Expression Correlates with a Reduced Sensitivity to 2'-Deoxycoformycin-Induced Growth Inhibition and Apoptosis in T-Cell Leukemia/Lymphomas
Clin. Cancer Res.,
January 15, 2004;
10(2):
508 - 520.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Zambello, L. Trentin, M. Facco, M. Siviero, S. Galvan, F. Piazza, A. Perin, C. Agostini, and G. Semenzato
Analysis of TNF-receptor and ligand superfamily molecules in patients with lymphoproliferative disease of granular lymphocytes
Blood,
July 15, 2000;
96(2):
647 - 654.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Schattner, J. Mascarenhas, I. Reyfman, M. Koshy, C. Woo, S. M. Friedman, and M. K. Crow
Chronic Lymphocytic Leukemia B Cells Can Express CD40 Ligand and Demonstrate T-Cell Type Costimulatory Capacity
Blood,
April 15, 1998;
91(8):
2689 - 2697.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
